Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00118703 · ClinicalTrials.gov registry record · Phase 3
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 350
- Enrollment target
NCT00118703 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 350 participants.
The verdict
NCT00118703, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 350 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with vasomotor rhinitis (VMR).
Interventions
- DRUG GW685698X
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2005-07-01 |
| Est. Completion | 2006-02-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00118703
The ClinicalTrials.gov registry entry for NCT00118703 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GW685698X is the first listed.
NCT00118703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00118703 about?
NCT00118703 is a clinical study titled "Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis". The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with vasomotor rhinitis (VMR).
What is the current status of trial NCT00118703?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 350 participants. The study started on 2005-07-01. Estimated completion is 2006-02-09.
What interventions are being tested in trial NCT00118703?
The interventions under investigation include: GW685698X (DRUG).
Who is sponsoring clinical trial NCT00118703?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.